pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
996
stories
Sep 15, 26
Blood centers can help biopharma scale cell and gene therapies
biospace
Sep 14, 26
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
biopharma dive
Sep 14, 26
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
fiercebiotech
Sep 14, 26
Unlocking cell surface protein research with site-specific labeling
biospace
Sep 14, 26
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
Sep 14, 26
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
Sep 13, 26
Centric Compounding Issues Nationwide Recall of Glutathione, Myer’s Cocktail, and Tri-Immune Boost Due to Elevated Endotoxin Levels
fda medwatch
Sep 11, 26
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
biopharma dive
Sep 11, 26
Frazier adds $1.1B+ to small and mid-sized biotech fund
biospace
Sep 11, 26
mRNA cancer vaccines’ biggest barriers to market
biopharma dive
Sep 11, 26
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
Sep 10, 26
Evergreen Fresh Sprouts LLC Recalls Broccoli Sprouts Because of Possible Health Risk
fda recalls
Sep 10, 26
The signal that changes everything: understanding MRD in oncology drug development
fiercebiotech
Sep 10, 26
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
biopharma dive
Sep 10, 26
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Sep 10, 26
A booming business on Wall Street would love more biotechs to quietly die
biopharma dive
Sep 10, 26
Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs
fiercebiotech
Sep 9, 26
BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
biospace
Sep 9, 26
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
biospace
Sep 9, 26
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
Sep 9, 26
Beeline flies into phase 3 as oral lupus drug soars past placebo
fiercebiotech
Sep 9, 26
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
Sep 8, 26
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
fiercebiotech
Sep 8, 26
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
biospace
Sep 8, 26
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
biospace
Sep 8, 26
Roivant's pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
biospace
Sep 8, 26
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
Sep 8, 26
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
biopharma dive
Sep 8, 26
Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
biospace
Sep 8, 26
Reeling from past failures, Parkinson's pipeline enters 'era of diversification'
biospace
← prev
page 16 of 34
next →